PERBANDINGAN EFEK TERAPI PIRASETAM DAN SITIKOLIN TERHADAP PERBAIKAN FUNGSI KOGNITIF PASIEN STROKE ISKEMIK

• Main Authors: , Munifah Wahyuddin, , Dr. Arief Nurrochmad, M.Sc., Apt.
• Format: Theses and Dissertations NonPeerReviewed
• Published: [Yogyakarta] : Universitas Gadjah Mada 2013
• Subjects: ETD
• Online Access: https://repository.ugm.ac.id/123253/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=63364
• Institution: Universitas Gadjah Mada

One of the impacts a stroke is cognitive impairment. Neuroprotector like pirasetam and stikolin is a drugs that can regulate cerebral function by improving the cognitive ability of the brain decreases, but its use is controversial and debated based on scientific research. In several hospitals in Makassar, both of neuroprotective sitikolin and piresetam widely used in patients with ischemic stroke. This study aims to determine comparison of therapeutic effects pirasetam and sitikolin to improved cognitive function ischemic stroke patients seen from MoCA�s (Montreal Cognitive Assessment) instrument. This study uses an observational with cohort design. Method of data collection was done prospectively which patients were grouped in two groups: 35 patients in the pirasetam and 27 patients in the sitikolin. Measuring the effectiveness pirasetam and sitikolin performed before and after (day 7) therapy using a scale MoCA. Therapeutic effects pirasetam and sitikolin characterized by an increase in the value of MoCA. Analysis of statistic showed that ischemic stroke patients who received treatment for 7 th days pirasetam based on total domains showed significant improvement in cognitive function were 0.000 (p <0.05), but no significant difference in each domain of cognitive. Ischemic stroke patients who received sitikolin therapy based on the total domain, showed a significant improvement in cognitive function is 0.000 (p <0.05) and the domain orientation 0.003 (p <0,05). There is a significant difference in the domain of conceptual thought in the 7 th day between therapy of pirasetam 0.31±0.631 with sitikolin 0,04±0.192 with a significance value of 0.033 (p <0.05) and for � MoCA there is not difference effects between pirasetam and sitikolin to improving cognitive function of patients with ischemic stroke significance value of 0.217 (p> 0,05).